ArticleiScience2020
PPARγ Cistrome Repression during Activation of Lung Monocyte-Macrophages in Severe COVID-19.
Article in iScience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- COVID-19, the disease that changed the world.Medicine and pharmacy reports · 2026Review
- Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinformatics and Experimental Approach.Annals of transplantation · 2026Article
- The dynamic interplay of M1/M2-like macrophages and adenosine deaminase activity modulates COVID-19 severity.Open medicine (Warsaw, Poland) · 2026Article
- Article
- Classification and regulatory interactions of key transcription factors in COVID-19.Frontiers in cellular and infection microbiology · 2025Review
- The prognostic significance of insulin resistance in COVID-19: a review.Journal of diabetes and metabolic disorders · 2024Review
- Role of innate immunity in SARS-CoV-2 infection.Biosafety and health · 2023Review
- The role of peroxisome proliferator-activated receptors in the modulation of hyperinflammation induced by SARS-CoV-2 infection: A perspective for COVID-19 therapy.Frontiers in immunology · 2023Review
- Identification of Transcriptome Biomarkers for Severe COVID-19 with Machine Learning Methods.Biomolecules · 2022Article
- Metabolic modeling of single bronchoalveolar macrophages reveals regulators of hyperinflammation in COVID-19.iScience · 2022Article
- The landscape of potential health benefits of carotenoids as natural supportive therapeutics in protecting against Coronavirus infection.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Gene Networks of Hyperglycemia, Diabetic Complications, and Human Proteins Targeted by SARS-CoV-2: What Is the Molecular Basis for Comorbidity?International journal of molecular sciences · 2022Article
- The COVID-19-diabetes mellitus molecular tetrahedron.Molecular biology reports · 2022Review
- D-dimer and CoV-2 spike-immune complexes contribute to the production of PGE2 and proinflammatory cytokines in monocytes.PLoS pathogens · 2022Article
- A path-based analysis of infected cell line and COVID-19 patient transcriptome reveals novel potential targets and drugs against SARS-CoV-2.Research square · 2022Article
- Seaweeds as Ingredients to Lower Glycemic Potency of Cereal Foods Synergistically-A Perspective.Foods (Basel, Switzerland) · 2022Article
- Network pharmacology and molecular docking-based investigations of Kochiae Fructus's active phytomolecules, molecular targets, and pathways in treating COVID-19.Frontiers in microbiology · 2022Article
- The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease.Molecular metabolism · 2022Review
- Targeting phytoprotection in the COVID-19-induced lung damage and associated systemic effects-the evidence-based 3PM proposition to mitigate individual risks.The EPMA journal · 2021Review
- HLA-dependent heterogeneity and macrophage immunoproteasome activation during lung COVID-19 disease.Journal of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The molecular mechanisms of cytokine storm in patients with severe COVID-19 infections are poorly understood. To uncover these events, we performed transcriptome analyses of lung biopsies from patients with COVID-19, revealing a gene enrichment pattern similar to that of PPARγ-knockout macrophages. Single-cell gene expression analysis of bronchoalveolar lavage fluids revealed a characteristic trajectory of PPARγ-related disturbance in the CD14+/CD16+ cells. We identified a correlation with the disease severity and the reduced expression of several members of the PPARγ complex such as EP300, RXRA, RARA, SUMO1, NR3C1, and CCDC88A. ChIP-seq analyses confirmed repression of the PPARγ-RXRA-NR3C1 cistrome in COVID-19 lung samples. Further analysis of protein-protein networks highlighted an interaction between the PPARγ-associated protein SUMO1 and a nucleoprotein of the SARS virus. Overall, these results demonstrate for the first time the involvement of the PPARγ complex in severe COVID-19 lung disease and suggest strongly its role in the major monocyte/macrophage-mediated inflammatory storm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.